Psyros Diagnostics (Psyros) has developed a ground-breaking single-molecule counting Point-of-Care (POC) technology for digital immunoassay. Only a small drop of blood is required to perform the test.
Strengths with Psyros’ ground-breaking technology
In addition to the existing PLD MicroFlex platform:
A brand new, innovative POC technology for digital immunoassay digitally counts individual molecules from a drop of blood.
The new ground-breaking technology also opens up the possibility of developing new POC tests in a wide range of clinical areas that were previously only possible to carry out in specialised laboratories.
Potential future applications include neurological pathologies (dementia, traumatic brain injury etc.), immune system dysfunction (sepsis, autoimmune disease) and virus detection, including Covid.
The new digital technology was incorporated into Prolight Diagnostics in early 2022 through the acquisition of the British company Psyros Diagnostics, which has developed a new, cutting-edge POC technology for digital immunoassay.
Today there is a clear and strong need for fast and accurate point of care testing. The market demands that more tests be moved out of the large hospital laboratories and closer to the patient and treating caregivers. Interest in POC testing increased significantly during the COVID-19 pandemic, which led to increased recognition of the value of rapid, simple, and effective testing close to the patient. Our ambition is to develop the best and most innovative POC systems in the market.
Psyros Diagnosics has developed a ground-breaking POC technology for digital immunoassay that digitally counts individual molecules from a drop of blood. This patent-pending technique, which also offers multiplexing capability, will allow measurement of biomarkers with extremely low detection levels (10-15 femtomolar) within about 10 minutes or less.
CEO, Prolight Diagnostics